142 related articles for article (PubMed ID: 20305607)
1. Amenorrhoea - consequence of combined treatment with sulpiride and risperidone in a patient suffering from schizophrenia.
Peitl MV; Pavlović E; Peitl A; Peitl V
Psychiatr Danub; 2010 Mar; 22(1):123-4. PubMed ID: 20305607
[TBL] [Abstract][Full Text] [Related]
2. Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder.
Peitl MV; Peitl V; Grahovac T; Pavlović E
Psychiatr Danub; 2010 Mar; 22(1):125-7. PubMed ID: 20305608
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
4. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Yuan HN; Wang CY; Sze CW; Tong Y; Tan QR; Feng XJ; Liu RM; Zhang JZ; Zhang YB; Zhang ZJ
J Clin Psychopharmacol; 2008 Jun; 28(3):264-370. PubMed ID: 18480682
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics and pituitary neoplasms in the WHO database.
Doraiswamy PM; Schott G; Star K; Edwards R; Mueller-Oerlinghausen B
Psychopharmacol Bull; 2007; 40(1):74-6. PubMed ID: 17285098
[TBL] [Abstract][Full Text] [Related]
6. [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Fric M; Laux G
Psychiatr Prax; 2003 May; 30 Suppl 2():S97-101. PubMed ID: 14509051
[TBL] [Abstract][Full Text] [Related]
7. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Tschoner A; Engl J; Rettenbacher MA; Kaser S; Ott HW; Fleischhacker WW; Patsch JR; Ebenbichler CF
J Clin Psychiatry; 2009 Feb; 70(2):293-4. PubMed ID: 19265646
[No Abstract] [Full Text] [Related]
8. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
[TBL] [Abstract][Full Text] [Related]
9. [Galactorrhea and secondary amenorrhea in hyperprolactinemia].
Wallmeroth A; Staub JJ
Praxis (Bern 1994); 2000 Aug; 89(34):1341-3. PubMed ID: 11021189
[No Abstract] [Full Text] [Related]
10. Acute and long-term treatment of catatonia with risperidone.
Hesslinger B; Walden J; Normann C
Pharmacopsychiatry; 2001 Jan; 34(1):25-6. PubMed ID: 11229618
[TBL] [Abstract][Full Text] [Related]
11. Risperidone induced galactorrhea: a case analysis.
Hariharan J; Mohsin J
WMJ; 2002; 101(8):41-3. PubMed ID: 12557612
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Bushe C; Shaw M
J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline-induced psychotic exacerbation in schizophrenic patients.
Chang SC; Chen CH; Lu ML
Gen Hosp Psychiatry; 2008; 30(4):378-80. PubMed ID: 18585544
[TBL] [Abstract][Full Text] [Related]
14. Re: Prolactin levels and adverse events in patients treated with risperidone.
Denisov MF
J Clin Psychopharmacol; 2002 Oct; 22(5):538-40; author reply 540-1. PubMed ID: 12352286
[No Abstract] [Full Text] [Related]
15. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
16. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
17. Hyperprolactinaemia - a risperidone side-effect.
Grahovac T; Ruzić K; Medved P; Pavesić-Radonja A; Dadić-Hero E
Psychiatr Danub; 2010 Mar; 22(1):120-2. PubMed ID: 20305606
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
[TBL] [Abstract][Full Text] [Related]
19. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Kopecek M; Bares M; Horacek J; Mohr P
Neuro Endocrinol Lett; 2006 Dec; 27(6):803-6. PubMed ID: 17187006
[TBL] [Abstract][Full Text] [Related]
20. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
Keller R; Mongini F
Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
